PMGC Holdings (ELAB) Shares Outstanding (2022 - 2026)
PMGC Holdings (ELAB) posted Shares Outstanding (Entity) of $444506.0 for Q1 2026, up 2084.09% sequentially from $20352.0 in Q4 2025, and up 6754.37% YoY from $6485.0 in Q1 2025.
PMGC Holdings (ELAB) Shares Outstanding (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Shares Outstanding (Entity) for 5 years, with the latest figure at $444506.0 in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 6754.37% year-over-year to $444506.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $444506.0 (up 6754.37% YoY) and the FY2025 annual result came in at $20352.0, up 2049.1% from the prior year.
- Shares Outstanding (Entity) advanced to $444506.0 in Q1 2026 per ELAB's latest filing, from $20352.0 in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $444506.0 in Q1 2026 and troughed at $81.0 in Q3 2022.
- A 5-year average of $34008.0 and a median of $161.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) grew 6.17% in 2023, then jumped 11612.77% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $81.0 in 2022, then advanced by 12.35% to $91.0 in 2023, then jumped by 940.66% to $947.0 in 2024, then soared by 2049.1% to $20352.0 in 2025, then soared by 2084.09% to $444506.0 in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $444506.0, $20352.0, and $22020.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | 4.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 444,506.00 |
| Dec 31, 2025 | 20,352.00 |
| Sep 30, 2025 | 22,020.00 |
| Jun 30, 2025 | 14,806.00 |
| Mar 31, 2025 | 6,485.00 |
| Dec 31, 2024 | 947.00 |
| Sep 30, 2024 | 188.00 |
| Jun 30, 2024 | 156.00 |
| Mar 31, 2024 | 147.00 |
| Dec 31, 2023 | 91.00 |
| Sep 30, 2023 | 85.00 |
| Jun 30, 2023 | 85.00 |
| Mar 31, 2023 | 83.00 |
| Dec 31, 2022 | 81.00 |
| Sep 30, 2022 | 81.00 |